ISS Backs Kenvue (KVUE) Deal, Investors Debate Tylenol and Litigation Risks

Group 1 - Kenvue Inc. is receiving institutional support for its proposed merger with Kimberly-Clark, which is valued at $40 billion, as recommended by Institutional Shareholder Services (ISS) [2] - The merger is expected to create positive synergies and advance strategic objectives, despite ongoing talcum litigation and concerns regarding Tylenol's active ingredient [2] - Meridian Hedged Equity Fund believes the market has overreacted to Tylenol safety concerns, noting minimal revenue impact and a lack of new scientific evidence [3] Group 2 - Kenvue's share price has decreased by 35% since its public listing in 2023, while Kimberly-Clark's share price has dropped by 17% since the merger announcement [4] - Kenvue focuses on consumer healthcare products, operating in Self Care, Skin Health, and Essential Health segments globally [4]